Pulse Biosciences (PLSE) Non-Current Deffered Revenue (2017 - 2018)
Pulse Biosciences (PLSE) posted quarterly Non-Current Deffered Revenue of $1.2 million for Q4 2018, down 25.73% year-over-year from $1.6 million in Q4 2017, and down 8.13% quarter-over-quarter from $1.3 million in Q3 2018.
Pulse Biosciences (PLSE) Non-Current Deffered Revenue (2017 - 2018) Analysis & Trends
Pulse Biosciences' Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $1.2 million for Q4 2018.
- In Q4 2018, Non-Current Deffered Revenue fell 25.73% year-over-year to $1.2 million; the TTM figure through Dec 2018 stood at $1.2 million (down 25.73% YoY), while the FY2018 annual figure was $1.2 million, down 25.73% from the prior year.
- Non-Current Deffered Revenue for Q4 2018 stood at $1.2 million, down from $1.3 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $1.8 million in Q2 2017, with the low at $1.2 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | - |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | - |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | - |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 170.95 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | - |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 13.90 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | - |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | 208.80 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | - |
| 10 | Pulse Biosciences | 3.50 Bn | 3.50 Bn | 161,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 1.20 Mn |
| Sep 30, 2018 | 1.30 Mn |
| Jun 30, 2018 | 1.41 Mn |
| Mar 31, 2018 | 1.51 Mn |
| Dec 31, 2017 | 1.61 Mn |
| Sep 30, 2017 | 1.72 Mn |
| Jun 30, 2017 | 1.82 Mn |